| 摘要 |
<p>PCT No. PCT/GB95/00156 Sec. 371 Date Jul. 19, 1996 Sec. 102(e) Date Jul. 19, 1996 PCT Filed Jan. 25, 1995 PCT Pub. No. WO95/20049 PCT Pub. Date Jul. 27, 1995This invention is directed toward a new type of herpesvirus particle (e.g., HSV-1), herein designated pre-viral DNA replication enveloped particles (PREPS), and methods of preparing said particles. These particles are non-infectious and can be prepared reliably to a high ratio of HSV-1 PREPS to infectious virus of at least 107:1. PREPS can be produced under conditions wherein viral DNA replication is blocked through the use of suitable drugs (e.g., acyclovir [ACV]; cytosine- beta -D-arabinofuranoside [ara C]) or by using an HSV mutant defective in viral DNA synthesis. Compositions comprising HSV-1 PREPS are disclosed wherein said particles have the following characteristics: a) the PREPS lack a viral capsid; b) the PREPS lack viral DNA; c) the PREPS contain reduced quantities of the proteins 273K (VP1-2), 82/81K (VP13/14), 57K (VP17, gD), and 40K, as compared to HSV-1 L particles; and d) the PREPS contain increased quantities of the proteins 175K (VP4, IE3), 92/91K (VP11/12), and 38K (VP22), as compared to HSV-1 L particles. These particles are useful, inter alia, for the generation of HSV-specific immunological and diagnostic reagents.</p> |
